Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Metastatic Castration-resistant Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Carcinoma, Renal Cell 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Nivolumab 22Specimen Handling 17pembrolizumab 13cabozantinib 13Magnetic Resonance Spectroscopy 13belzutifan 12Ipilimumab 12lenvatinib 7Axitinib 7CTLA-4 Antigen 6Biopsy 6atezolizumab 4Sunitinib 4tivozanib 3Surveys and Questionnaires 3Immunoglobulin G 3Everolimus 3Disulfides 3relatlimab 2pazopanib 2palbociclib 2aldesleukin 2Watchful Waiting 2Standard of Care 2Radiosurgery 2Practice Guidelines as Topic 2Nephrectomy 2Bevacizumab 2zimberelimab 1ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × radium Ra 223 dichloride × 30 days × Clear all
NCT04071223 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

National Cancer Institute (NCI)

Phase 2 Active not recruiting
134 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡